Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.
The pharmacokinetics of orally administered mefloquine were determined in six healthy male subjects and in six ulcer patients before and after a 3-day course of cimetidine (400 mg morning and evening). Peak plasma concentrations Cmax and AUC0-infinity were similarly and significantly (P < 0.05) increased after cimetidine pretreatement in both healthy subjects and peptic ulcer patients Cmax was increased by 42.4% and 20.5% while AUC0-infinity was increased by 37.5% in healthy and peptic ulcer subjects respectively. The values of t1/2ab absorption and t1/2 beta elimination, total crearance CLT/F and volume of distribution were altered to varying levels after cimetidine treatment but the changes were not statistically significant in both healthy and peptic ulcer subjects. The established long t1/2 beta and this apparent interaction between mefloquine and cimetidine which resulted in increased mefloquine plasma concentration might be of clinical significant in patients with neurological/psychiatric history.
Kolawole
J A
JA
Department of Pharmaceutical Chemistry, University of Jos, Jos, Nigeria.
Mustapha
A
A
Abudu-Aguye
I
I
Ochekpe
N
N
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000962:Antimalarials / Q000493:pharmacokinetics*; D002927:Cimetidine / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D015767:Mefloquine / Q000493:pharmacokinetics*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000378:metabolism*
D000897:Anti-Ulcer Agents; D000962:Antimalarials; D002927:Cimetidine; D015767:Mefloquine